• 서울대학교 대학원 의학박사
• 서울대학교 대학원 의학석사
• 서울대학교 의과대학 졸업

• 현재  | 이대서울병원 혈액종양내과 임상교수
• 2023-2026  | 가천의대 길병원 진료교수
• 1995-2023  | 가천의대 교수
• 1993-1995  | Research Fellow 미국 University of Arkansas for Medical Science
• 1987-1993  | 보라매병원 내과 서울대학교 의과대학 임상강사, 조교수
• 1986-1987  | 서울대학교병원 혈액종양내과 전임의
• 1986  | 내과 전문의 취득
• 1983-1986  | 서울대학교 내과 전공의 수료

• 2022 | 정부근정포장
• 2018 | 대한조혈모세포이식학회 공로상
• 2016 | 대한혈액학회 학술상
• 2002 | 대한s 혈액학회 공로상

• 2015-2016  | 대한조혈모세포이식학회 회장
• 2015-2016  | 대한조혈모세포이식학회감사
• 2011-2025  | Asian Myeloma Network EC member
• 2011-2013  | 대한혈액학회 무임소이사
• 2008-현재  | International Myeloma Working Group (IMWG)
• 1999-2002  | 대한조혈모세포이식학회 편집이사

•  Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients.  Cancer Res Treat. 2026-08. 
•  Response kinetics as a dynamic prognostic marker in patients with multiple myeloma.  Leukemia. 2026-07. 
•  Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea.  Cancer Res Treat. 2026-07. 
•  A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906).  Cancer Res Treat. 2026-07. 
•  The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.  Haematologica. 2026-06. 
•  Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).  Cancer Res Treat. 2026-05. 
•  Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.  Blood Cancer J. 2026-03. 
•  A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803).  Br J Haematol. 2026-02. 
•  Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.  Int J Hematol. 2026-02. 
•  Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.  N Engl J Med. 2026-02. 
•  Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.  Cancers (Basel). 2026-01. 
•  A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma.   2025-08-13. 
•  Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study.   2025-06-04. 
•  A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.   2025-10-01. 
•  Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry.   2025-05-07. 
•  A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906).   2025-06-30. 
•  Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea.   2025-07-30. 
•  Randomized Phase 3 study of pomalidomidecyclophosphamide dexamethasone versus pomalidomidedexamethasone in relapse or refractory myeloma: an AsianMyeloma Network study (AMN003).   2025. 
•  Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone. Yi, J.H., Park, SS., Min, CK.   2025. 
•  Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.   2025-10-29. 
•  A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803) Jung SH, Kim D, Lee JJ, Kim K, Min CK, Lee JH, Lee WS, Lee JH, Lee GW, Kim MK, Shin HJ, Kim HJ, Yi JH, Lee HS.   2025-11-28. 
•  A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.   2024-01-15. 
•  Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.   2024-07-01. 
•  Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.   2024-07. 
•  Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.   2024-06-06. 
•  Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study.   2024-11-01. 
•  Busulfan, Melphalan, and Etoposide (Bume) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)Cancer Res Treat.   2023-01. 
•  Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.   2023-03-01. 
•  36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.   2023-02. 
•  Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study.   2023-04. 
•  Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.   2023-10. 
•  Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.   2023-06-26. 
•  Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).   2023. 
•  Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.   2023-10-23. 
•  Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) Sung-Hoon Jung1* Ga-Young Song1 Je-Jung Lee1 Joon Ho Moon2 Dajung Kim3 Min Kyoung Kim4 Hyo Jung Kim5 Yeung-Chul Mun6 Won Sik Lee7 Young Rok Do8 Jae Hoon Lee9 Jin Seok Kim10 Front.   2023. 
•  Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.   2022-02. 
•  Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.   2022-08. 
•  Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma..   2022. 
•  Low-dose abdominopelvic computed tomography in patients with lymphoma: An image quality and radiation dose reduction study.   2022-08-11. 
•  Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea.   2022-06-30. 
•  Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.   2022-07. 
•  Impact of ixazomib-lenalidomide-dexamethasone therapy onoverall survival in multiple myeloma patients: Analysis of theemerging-markets subgroup of the TOURMALINE-MM1 trial.   2022-08-31. 
•  Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909).   2022-12. 
•  Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.   2022-11-14. 
•  Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.   2022-11-21. 
•  Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone..    
•  Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK.    
•  Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).Liu, J; Hu, X; Jia, Y; Lu, J; Lee, JH; Kim, K; Chen, W; Liu, A; Liu, Y; Chen, Q; Zhang, C; Suh, C; Kim, MK; Zhou, F; Chng, WJ; Kumar, SK; Durie, B; Hou, J; Fu, W; Du, JLeukemia, 2021 vol.    
•  A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma.   2020-02. 
•  The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).   2020-02. 
•  Incorporating hematopoietic stem-celltransplantation after second-line carfilzomiblenalidomide-dexamethasone (KRd)Ja Min Byun , Sung-Soo Yoon, Youngil Koh, Chang-Ki Min, Jae Hoon Lee, Jaemin Jo,Hyunkyung Park, Jiyun Lee, Ka-Won Kang, Yoojin Lee and the Korean Multiple Myeloma Working Party (KMMWP) Therapeutic Advances in Hematology 11:1-10,2020.    
•  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Simkovic, Polina Kaplan, Iryna Kraychok, Arpad Illes, Javier de la Serna, Sean Dolan, Phillip Campbell, Gerardo Musuraca, Abraham Jacob, Eric Avery, Jae Hoon Lee, Wei Liang, Priti Patel, Cheng Quah, and Wojciech Jurczak.   2020-09-01. 
•  Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia.   2020-07. 
•  Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults.   2020. 
•  Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis Ga-Young Song, Sung-Hoon Junga, Je-Jung Leea , Jin Seok Kimb , Chang-Ki Minc , Kihyun Kimd , Yunsuk Choie , Hyeon-Seok Eomf , Young Don Joog , Sung-Hyun Kimh , Jae-Yong Kwaki , Hye Jin Kangj , Jae Hoon Leek , Ho Sup Leel , Yeung-Chul Munm, Joon Ho Moonn , Sang Kyun Sohnn , Seong Kyu Parko , Yong Parkp , Ho-Jin Shinq and Sung-Soo YoonrLEUKEMIA & LYMPHOMA 2020, VOL.    
•  Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.   2019-01-19. 
•  Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.   2019-01-01. 
•  Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.   2019-04. 
•  Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients.   2019-02-28. 
•  Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.   2019-03. 
•  A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.   2019-03-23. 
•  Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.   2019-05-02. 
•  Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.   2019-09. 
•  Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.   2019-10. 
•  Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.   2019-07-09. 
•  A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.   2019-07. 
•  Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.   2019-10-08. 
•  Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.   2019-10-16. 
•  Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.   2019. 
•  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.   2019-12-07. 
•  Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.    
•  Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).   2018-05-24. 
•  Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.   2017-09-18. 
•  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.   2018-02-08. 
•  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.   2018-01-25. 
•  Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.   2018-01. 
•  A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.   2018-06. 
•  The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma.   2018-09-25. 
•  Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.   2018-11-23. 
•  Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.   2019-03. 
•  Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.   2018-12-10. 
•  Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.   2017-02. 
•  Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the FIRST Trial.   2017-03. 
•  Deacetylase Inhibitors: an Advance in Myeloma Therapy?Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG.Expert Rev Hematol.    
•  Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.   2017-01. 
•  A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.   2017-06-06. 
•  Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome.   2016-11-08. 
•  Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS working party.   2017-05-29. 
•  The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).   2017-06-16. 
•  Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.   2017-10. 
•  Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.   2017-11. 
•  Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy.   2017-12. 
•  Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial.   2017-09. 
•  Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort.   2017-09. 
•  Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.   2017-09-18. 
•  Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia.   2016-01. 
•  Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults.   2020. 
•  Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.   2016. 
•  A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera.   2016-03. 
•  Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment.   2016-02-11. 
•  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.   2016-01. 
•  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.   2016. 
•  Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.   2016-01. 
•  Prgostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy.   2016-10. 
•  A successful planned pregnancy and delivery with eculizumab maintenance in a woman with Paroxysmal Nocturnal Hemoglobinuria.   2016. 
•  Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.   2016-06. 
•  Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma.   2016-06. 
•  Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.   2016-07. 
•  Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study.   2016-08. 
•  Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).   2016-08-16. 
•  Recent Advances in Multiple Myeloma: a Korean Perspective.   2016-09. 
•  Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.   2016-09. 
•  Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.   2016-10-14. 
•  Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.   2016-10. 
•  Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.   2016-11-08. 
•  A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer.   2012-02. 
•  Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.   2015-03. 
•  Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.   2015. 
•  Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.   2015-04. 
•  Nilotinib combined with multi-agent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.   2015. 
•  A Case of Primary Breast Diffuse Large B-Cell Lymphoma Treated with Chemotherapy Followed by Elective Field Radiation Therapy: A Brief Treatment Pattern Review from a Radiation Oncologist’s Point of View.   2015. 
•  Long-term follow-up of imatinib plus combination chemotherapy in for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.   2015-11. 
•  Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.   2015-09-04. 
•  Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.   2015-11. 
•  Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.   2015-12. 
•  Successful Treatment with Low-dose Rituximab in a Patient with Plasma Exchange-refractory Idiopathic Thrombotic Thrombocytopenic Purpura.    
•  A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.   2014-01. 
•  High-dose Etoposide plus G-CSF as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma (CISL) Hyun SY, Cheong JW, Lim SJ, Min YH, Yang DH, Ahn JS, Ryoo HM, Do YR, Lee HS, Lee JH , Oh SY, Suh C, Yhim HY, Kim JS.    
•  Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.   2014-01. 
•  Acute myeloid leukemia with persistent marrow aplasiaafter chemotherapy treated with reduced intensity allo-stem cell transplantation.   2013. 
•  IMWG consensus on risk stratification in multiple myeloma.   2014-02. 
•  Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer.   2014-06. 
•  Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis.   2014-06. 
•  Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.   2014-06. 
•  Clinical profiles of multiple myeloma in Asia - an Asian Myeloma Network (AMN) study.   2014-07. 
•  Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.   2014-08. 
•  Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.   2014-08. 
•  Prognostic Value of Metabolic Tumor Volume Estimated by 18F-FDG PositronEmission Tomography/Computed Tomography in patients with diffuse large B-celllymphoma of stage II or III disease.    
•  Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.   2014-09. 
•  Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma.   2014-10. 
•  Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea.   2014. 
•  Panobinostat, bortezomib and dexamethasone in patientswith relapsed or relapsed and refractory multiple myeloma:a multicentre, randomised, double-blind phase 3 trial.   2014-10. 
•  Acute Myeloid Leukemia with Persistent Marrow Aplasia after Chemotherapy.    
•  Treated with Reduced-Intensity Allogeneic Stem Cell Transplantation.   2014. 
•  Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.   2014-12. 
•  Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.   2014-12. 
•  Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.   2014. 
•  Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: Results of multicenter analysis.   2013-01. 
•  Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation.   2013-01. 
•  A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.   2013-02. 
•  Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project.   2013-03. 
•  Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.   2013-03. 
•  Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.   2013-04. 
•  Management of treatment-emergent peripheral neuropathy in multiple myeloma.   2012-04. 
•  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group.Leukemia.    
•  Limitation in the assessment of baseline lymphomatous bone marrow involvement by FDG-PET/CT scan.   2013-04. 
•  Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.   2013-05. 
•  Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.   2013. 
•  N-ras Mutation Detection by Pyrosequencing in Adult Patients with Acute..    
•  Myeloid Leukemia at a Single Institution.   2013-05. 
•  Comparison of characteristics of bacterial bloodstream infection between adult patients with allogenic and autologous hematopoietic stem cell transplantation.   2013-06. 
•  Plerixafor use for peripheralblood stem cell mobilization inKorea.   2013-06. 
•  The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.   2013-09. 
•  Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma.   2013-08-31. 
•  Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia.   2013-11. 
•  Management of multiple myeloma in Asia: resource-stratified guidelines.   2013-11. 
•  Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma.   2013. 
•  A Case of Immune Hemolytic Anemia due to Autoantibodies Against C and e Antigens in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome.   2012. 
•  Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.   2012-01. 
•  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.   2012-01. 
•  Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.   2012-02. 
•  Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.   2012-05. 
•  A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas.   2012-03. 
•  Management of treatment-emergent peripheral neuropathy in multiple myeloma.   2012-04. 
•  A case of rectal mucosa-associated lymphoid tissue lymphoma diagnosed by endoscopic unroofing technique.   2012-06-25. 
•  Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.   2011-10. 
•  Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.   2012-07-01. 
•  Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.   2012-08. 
•  Clinical characteristics and outcomes of primary bone lymphoma. in Korea.   2012. 
•  Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.   2012. 
•  CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.   2012-12. 
•  Cervical lymphadenopathy mimicking angioimmunoblastic T-cell lymphoma after dapsone-induced hypersensitivity syndrome.   2012. 
•  Usefulness of 18F-FDG PET/CT for the evaluation of bone marrow involvement in patients with high grade Non-Hodgkin's lymphoma.   2012. 
•  Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets.   2011. 
•  Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.   2011-02. 
•  Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.   2011-06. 
•  Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.   2011. 
•  Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.   2011-06-21. 
•  Irinotecan and Cisplatin Combination Chemotherapy PlusConcurrent Thoracic Irradiation for Patients with LimitedDisease Small Cell Lung Cancer.   2011. 
•  Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.   2011-10. 
•  Multicenter retrospective analysis of 581 patients withprimary intestinal non-Hodgkin lymphoma from theConsortium for Improving Survival ofLymphoma (CISL)Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH , Oh S, Park KW, Suh C, Kim WS.   2011-07-29. 
•  Presumed intraocular natural killer/T-cell lymphoma combined with nasal lymphoma.   2011. 
•  A Combination of Melphalan, Prednisone, and 50 mgThalidomide Treatment in Non-Transplant-CandidatePatients with Newly Diagnosed Multiple Myeloma.   2011. 
•  Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.   2010. 
•  Induction Treatment With Cyclophosphamide,Thalidomide, and Dexamethasone in NewlyDiagnosed Multiple Myeloma: A Phase II Study.   2010. 
•  Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.   2010. 
•  Clinical characteristics of lung cancer diagnosed from 2006 to 2008: Data from Gachon University Gil Hospital.   2010. 
•  Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.   2010. 
•  Re-analysis of the Outcomes of Post-Remission Therapy for Acute Myeloid Leukemia with Core Binding Factor According to Years of Patient Enrolment.   2010. 
•  Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.   2010. 
•  Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.   2011. 
•  Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.   2010. 
•  Bortezomib, thalidomide, dexamethasone induction therapyfollowed by melphalan, prednisolone, thalidomide consolidationtherapy as a first line of treatment for patients with multiplemyeloma who are non-transplant candidates: resultsof the Korean Multiple Myeloma Working Party (KMMWP) Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.   2010. 
•  Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.   2010. 
•  Oxalipatin, 5-fluorouracil and Leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer.   2010. 
•  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.   2010. 
•  Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.   2010. 
•  Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.   2010-06-22. 
•  Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-small cell lung cancer.   2010. 
•  Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report.   2010-09. 
•  The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.   2010-10. 
•  A Case of Non-secretory Myeloma with Crystal-storing Histiocytosis.   2010-12. 
•  Additional rituximab-CHOP (R-CHOP) versus involved- field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma :a retrospective analysis.   2010. 
•  Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.   2009. 
•  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.   2009-02. 
•  Complete Remission Status before Autologous StemCell Transplantation Is an Important Prognostic Factorin Patients with Multiple Myeloma Undergoing UpfrontSingle Autologous Transplantation.   2009. 
•  Different clinical importance of FLT3 internal tandem duplications in AML annals according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.   2009. 
•  Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype.   2009. 
•  Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.   2009. 
•  International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.   2009. 
•  Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung.   2009-06. 
•  International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.   2009-09. 
•  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).   2009. 
•  Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry.    
•  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review R Fonseca1, PL Bergsagel, J Drach, J.Shaughnessy, N Gutierrez, K Stewart, G Morgan, B Van Ness, M Chesi1, S Minvielle, A Neri, B Barlogie, WM Kuehl, P Liebisch, F Davies, S Chen-Kiang, BGM Durie, R Carrasco, Orhan Sezer, TonyReiman, Linda Pilarski1 and H Avet-Loiseau.   2009. 
•  Prolonged extreme thrombocytosis in a postsplenectomy patient with hereditary spherocytosis.   2009. 
•  Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors.   2008. 
•  Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.   2008. 
•  Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.   2008. 
•  Protective Role of CYP1A1*2A in the Development of MultipleMyeloma.   2008. 
•  Prospective Pilot Study of Consolidation Chemotherapy with Docetaxel and Cisplatin After Concurrent Chemoradiotherapy for Advanced Head and Neck Cancer.   2008. 
•  A Randomized Double-Blind Placebo-Controlled Study of Low-Dose Intravenous Lorazepam to Reduce Procedural Pain During Bone Marrow Aspiration and Biopsy.   2008. 
•  Epstein-Barr Virus-Positivity in Tumor has noCorrelation with the Clinical Outcomes of Patientswith Angioimmunoblastic T-cell Lymphoma.   2008. 
•  Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer : a noncomparative phase II study.   2008. 
•  A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.   2008. 
•  Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.   2008. 
•  Prognostic implications of the immunophenotype in biphenotypic acute leukemia.   2008. 
•  Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.: Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, Nam SH, Kwon JH, Kim HJ, Sohn SK, Won JH, Lee JH , Suh C, Yoon SS, Kim HJ, Kim I, Do YR, Lee WS, Joo YD, Shin HJ.Clin Lymphoma Myeloma.    
•  Low Frequency and Variability of FLT3 Mutations in Korean Patientswith Acute Myeloid Leukemia.   2008. 
•  The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.   2008-08. 
•  Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.   2007-02-15. 
•  MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: A case-control study in Korea.   2007. 
•  Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.   2007. 
•  Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung Cancer.   2007. 
•  Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.   2007-10. 
•  Association of the 5,10-Methylenetetrahydrofolate Reductase(MTHFR C677T and A1298C) Polymorphisms in KoreanPatients with Adult Acute Lymphoblastic Leukemia.   2007. 
•  JAK2(V617F) Mutation in Korean Patients with Essential Thrombocythemia..   2007-04. 
•  Extranodal NK/T-Cell Lymphoma, nasal-type: a prognostic model from a retrospective multi-center study.   2006-02-01. 
•  Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.   2006. 
•  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.   2006. 
•  Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy.   2006. 
•  Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil.   2006-02. 
•  A complex, four-way, variant 15;17 translocation in acute promyelocytic leukemia.   2006. 
•  High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.   2006. 
•  A phase II study of etoposide(VP-16), ifosfamide, and carboplatin combination chemotherapy plus concurrent thoracic irradiation for limited stage small cell lung cancer.   2006. 
•  Carboplatin, ifosphamide, and etoposide chemotherapy for extensive-disease small cell lung cancer.   2006. 
•  A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.   2006. 
•  Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CJ, Yoo SJ, Kim HC, Chun HG, Lee JH , Lee DS.    
•  New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.   2006. 
•  Two cases of interstitial pneumonitis caused by Rituximab therapy.   2006. 
•  Vascular complications in patients with essential thrombocythemia.   2006. 
•  Thalidomide for metastatic hepatocellular carcinoma : A pilot study.   2006. 
•  A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer.   2006. 
•  The Diagnostic Usefulness of Janus Kinase 2 Mutation in non-BCR/ABL Myeloproliferative Disorders.   2006. 
•  Epidemiological changes of multiple myeloma in Korea.    
•  Efficacy and safety of Leukoup(R) (Filgrastim, rhG-CSF) for chemotherapy induced neutropenia in solid tumors. A randomized, multicenter, phase III comparison with Grasin.   2005. 
•  Changes in quality of life during the palliative chemotherapy for solid cancer.   2005. 
•  A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.   2005. 
•  Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.   2005. 
•  Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.   2005. 
•  The clinical efficacy of Helicobacter pylori eradication in patients with Helicobacter-positive chronic thrombocytopenia purpura.   2005. 
•  Heparin-induced thrombocytopenia in patient with acute coronary syndrome : incidence and clinical feature, retrospective study.   2005. 
•  High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral BloodProgenitor Cell Mobilization.   2005. 
•  A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma.   2005. 
•  Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience.   2005. 
•  Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.   2005. 
•  Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.   2005. 
•  A case of human toxocariasis presented with hypereosinophilia.   2005. 
•  Gemcitabine plus Carboplatin in patients with advanced non-small cell lung cancer.   2005. 
•  High dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma.   2005. 
•  First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.   2004. 
•  Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma. A case report.   2004. 
•  Clinical features of Waldenstrom Macroglobulinemia in Korea.   2004. 
•  A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy.   2004. 
•  Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation.   2003. 
•  High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma.   2003. 
•  A phase II study of Paclitaxel and Cisplatin combination chemotherapy in advanced non-small cell lung cancer.   2003. 
•  A multicenter, phase III trail of Leucogreen (G-CSF) for chemotherapy-induced neutropenia in solid tumors.   2003. 
•  Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.   2003-03. 
•  Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil for Advanced Gastric Carcinoma.   2002. 
•  Comparison of Microvessel Density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications:multicenter trial.   2002. 
•  A case of acquired amegakaryocytic thrombocytopenia responding to immunosuppressive therapy.   2002. 
•  Autologous Peripheral Stem Cell Transplantation in a Patient with Multiple Myeloma and End-stageRenal Disease.   2002. 
•  Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia.   2003. 
•  Detection of IgH and Cyclin D1 gene Rearrangement with Interphase FISH in Multiple Myeloma.   2002. 
•  Salvage therapy with thalidomide in patients with multiple myeloma.   2002. 
•  Combination Chemotherapy with Vinorelbine and Ifosfamide for advanced non- small cell lung cancer.   2001. 
•  A Case of Iatrogenic Wernicke's Encephalopathy Following Chemotherapy and Total Parenteral Nutrition.   2001. 
•  A case of Waldenstrom's macroglobulinemia presented as a compression fracture of spine.   2001. 
•  Cytarabine and Idarubicin Induction Chemotherapy in Patients with Acute Myelogenous Leukemia.   2001. 
•  Prognostic value of AML1/ ETO fusion transcripts in patients with acute myelogenous leukemia.   2001. 
•  Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leukovorin in 5-Fluorouracil-Pretreated Patients with Metastatic Colorectal Cancer.   2001. 
•  High dose chemotherapy with autologous peripheral blood stem cell transplantation for high risk breast cancer patients : A phase II multicenter trial.   2001. 
•  A Phase II Study of Genexol® ( paclitaxel ) in Metastatic Breast Cancer.   2001. 
•  High dose chemotherapy with Ifosphamide, Carboplatin, and Etoposide followed by autologous stem cell transplantation in breast cancer.   2000. 
•  Combination chemotherapy with Vinorelbine and Epirubicin (VE) in patients with advanced breast cancer.   2000. 
•  High dose chemotherapy with autologous stem cell transplantation in multiple myeloma.   1999. 
•  Complete remission in a patient with multiple myeloma after high dose melphalan and CD34 + selected autologous transplantation.   1998. 
•  4 cases of typhlitis, developed in neutropenic state and treated with medical conservative management.   1997. 
•  A case of metastatic epididymal and the other metastatic testicular carcinoma from sigmoid carcinoma.   1997. 
•  Effect of Cytosine arabinoside and Daunorubicin (AD) combination chemotherapy in acute myelogenous leukemia.   1997. 
•  Allogeneic bone marrow transplatation as treatment for chronic myelogenous leukemia.   1994. 
•  Phase II trial of recombinant interferon-gamma (LBD-001) in patients with malignancies.   1992. 
•  Treatment of intermediate-grade non-Hodgkin's lymphomas with CAMP-MOB combination chemotherapy.   1992. 
•  The Mechanism of In Vitro Colony Formation Inhibition of Interferon-γ onNormal Hemopoietic Stem Cell (CFU-GM, BFU-E)A thesis for the degree of Doctor of Philosophy in Medicine, 1991 (Korean).   1991. 
•  A study on cell dose and effect of fetal thymic cell transplantation to overcome graft rejection in fetal liver cell transplantation in mice.   1990. 
•  Intrapleural administration of OK-432 in patients with malignant pleural effusion.   1989. 
•  Remission induction with Vincristine, Prednisone, Daunorubicin, L-asparaginase in adult acute lymphocytic leukemia.   1990. 
•  Changes of factor VIII and von Willebrand factor in hemorrhagic fever with renal syndrome.   1990. 
•  Combination chemotherapy with cyclophosphamide, adriamycin, and cisplatin(CAP) in patients with advanced ovarian cancer.   1990. 
•  Plasminogen activator inhibitor in human platelets.   1990. 
•  Scintigraphy with Indium-111-oxine labled leukocytes for localization of abscesses.   1990. 
•  Antilymphocyte globulin, methylprednisone and oxymetholone combinatoion therapy in patients with aplastic anemia.   1990. 
•  Clinical observation on Staphylococcus Aureus bacteremia.   1990. 
•  Study on the mechanism of pseudothrombocytopenia.   1990. 
•  Microangiopathic hemolytic anemia (MAHA) associated with cancer.   1990. 
•  Vascular involvement and frequency of anticardiolipin antibody in patients with Behcet's disease.   1990. 
•  A case of primary gastric tuberculosis.   1989. 
•  Neoadjuvant chemotherapy with 5-fluorouracil infusion and cisplatin followed by radiotherapy for locally advanced head and neck cancer.   1988. 
•  5-FU infusion and cisplatin in patients with disseminated or recurrent head and neck cancer.   1988. 
•  Combination chemotherapy with Aclacinomycin, 6-Thioguanine and Ara-C in patients with acute myelogenous leukemia.   1988. 
•  5-Fluorouracil continuous infusion and Mitomycin-C (FM) combination chemotherapy for metastatic or recurrent colorectal cancer.   1987. 
•  Dimethyl Triazeno Imidazole Carboxamide (DTIC) Therapy in metastatic malignant melanoma.   1987. 
•  Vinka alkaloid for the treatment of refractory idiopathic thrombocytopenic purpura.   1987. 
•  Adult T-cell leukemia-the first case in republic of Korea.   1987. 
•  Bone marrow findings in Korean hemorrhagic fever.   1985. 
•  A clinical study on myelodysplastic syndrome.   1985. 
•  Hematologic findings of myelodysplastic syndrome.   1984.